News Releases

Keyword Search

Feb-22-2021
Oncternal Therapeutics Reports Granting of an Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Jan-28-2021
Oncternal Therapeutics Announces the Appointment of Dr. Rosemary Mazanet to the Board of Directors
Jan-14-2021
Oncternal Therapeutics, Inc. Confirms Lentigen Technology, Inc. to Manufacture Lentiviral Vectors for Its ROR1-targeting CAR-T Cell Therapy Program
Jan-07-2021
Oncternal Therapeutics and Karolinska Institutet Establish Collaboration for Research and Development of ROR1-targeting CAR-T and CAR-NK Cell Therapies
Jan-05-2021
Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
Dec-14-2020
Oncternal Therapeutics Announces Closing of $86.2 Million Bought Deal and Full Exercise of Option to Purchase Additional Shares
Dec-09-2020
Oncternal Therapeutics Increases Previously Announced Bought Deal to $75.0 Million
Dec-09-2020
Oncternal Therapeutics Announces $40.0 Million Bought Deal Offering
Dec-07-2020
Oncternal Therapeutics Announces Presentation of Interim Phase 1/2 Data Update for Cirmtuzumab in Combination with Ibrutinib at ASH 2020 Virtual Annual Meeting
Nov-17-2020
Oncternal Therapeutics Increases Previously Announced Bought Deal to $22.5 Million